Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 25092775

Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
J Clin Oncol
Publication date
2015 Jan 1
First author
Sikov WM

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2015 Jan 1;33(1):1-3. doi: 10.1200/JCO.2014.57.7890.
    note
    Source null
    related pmid
    25332246
    relationship
    Comment in
  2. citation
    Bull Cancer. 2014 Dec;101(12):1063. doi: 10.1684/bdc.2014.2051.
    note
    Source null
    related pmid
    25776517
    relationship
    Comment in
  3. citation
    Bull Am Coll Surg. 2016 Apr;101(4):40-2.
    note
    Source null
    related pmid
    27337767
    relationship
    Comment in

Authors and identifiers

  1. name
    Sikov WM
    type
    Author
  2. name
    Berry DA
    type
    Author
  3. name
    Perou CM
    type
    Author
  4. name
    Singh B
    type
    Author
  5. name
    Cirrincione CT
    type
    Author
  6. name
    Tolaney SM
    type
    Author
  7. name
    Kuzma CS
    type
    Author
  8. name
    Pluard TJ
    type
    Author
  9. name
    Somlo G
    type
    Author
  10. name
    Port ER
    type
    Author
  11. name
    Golshan M
    type
    Author
  12. name
    Bellon JR
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Sikov WM
    type
    Author
  2. name
    Berry DA
    type
    Author
  3. name
    Perou CM
    type
    Author
  4. name
    Singh B
    type
    Author
  5. name
    Cirrincione CT
    type
    Author
  6. name
    Tolaney SM
    type
    Author
  7. name
    Kuzma CS
    type
    Author
  8. name
    Pluard TJ
    type
    Author
  9. name
    Somlo G
    type
    Author
  10. name
    Port ER
    type
    Author
  11. name
    Golshan M
    type
    Author
  12. name
    Bellon JR
    type
    Author
bibliography ids
  1. nci-bib-d580e68e41e975c806279045
book metadata
content sha256
d6f3140d3b8b9b518262e5e540bd61c4367f9e064f3cf1dd95749d7ad30be032
document type
citation
dois
  1. 10.1200/JCO.2014.57.0572
electronic publication date
display
2014 Aug 4
precision
day
year
2014
evidence scope
bibliographic_metadata_only
id
pubmed:25092775
immutable id
pubmed:25092775@d6f3140d3b8b9b518262e5e540bd61c4367f9e064f3cf1dd95749d7ad30be032
journal
abbreviation
J Clin Oncol
issn electronic
1527-7755
issn print
0732-183X
issue
1
name
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
nlm unique id
8309333
pages
13-21
volume
33
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    J Clin Oncol. 2015 Jan 1;33(1):1-3. doi: 10.1200/JCO.2014.57.7890.
    note
    Source null
    related pmid
    25332246
    relationship
    Comment in
  2. citation
    Bull Cancer. 2014 Dec;101(12):1063. doi: 10.1684/bdc.2014.2051.
    note
    Source null
    related pmid
    25776517
    relationship
    Comment in
  3. citation
    Bull Am Coll Surg. 2016 Apr;101(4):40-2.
    note
    Source null
    related pmid
    27337767
    relationship
    Comment in
outcomes validated
false
pmid
25092775
provenance
batch id
69903be8ceab8801c81a
provider
NCBI PubMed ESummary
record sha256
354943a62cb4b6a3f3c5b3363caa6168183922cc464205a0943113463dac312c
response sha256
1e367491c3c459a93f45b3db99ca1f9293ed2287c48bdf758bb088ffcd7c96eb
retrieved at
2026-09-09T23:47:05.208886+00:00
publication date
display
2015 Jan 1
precision
day
year
2015
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, N.I.H., Extramural
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/25092775/
title
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

Preserved source evidence · Not medical advice